Loading patent…
OwnerKimberly O. Cameron, HuaZhu Ke +2inventors
InventorsKimberly O. Cameron, HuaZhu Ke, Bruce A. Lefker, David D. Thompson
Estimating the term…
This invention is directed to methods and pharmaceutical compositions comprising prostaglandin agonists which are userful to prevent bone loss, restore or augment bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass, such as osteoporosis, and/or bone defects in vertebrates, and particularly mammals, including humans. This invention specifically relates to methods and pharmaceutical compositions comprising combinations of EP2 receptor selective agonists and EP4 receptor selective agonists and to methods and pharmaceutical compositions comprising agents which are agonists for both the EP2 receptor and the EP4 receptor.
A pharmaceutical composition comprising an EP2 receptor selective agonist, a prodrug thereof or a pharmaceutically acceptable salt of said EP2 receptor selective agonist or of said prodrug, and an EP4 receptor selective agonist, a prodrug thereof or a pharmaceutically acceptable salt of said EP4 receptor selective agonist or of said prodrug.
A method of treating a condition which presents with low bone mass in a mammal comprising administering to said mammal an EP4 receptor selective agonist, a prodrug thereof or a pharmaceutically acceptable salt of said EP4 receptor selective agonist or of said prodrug and an EP2 receptor selective agonist, a prodrug thereof or a pharmaceutically acceptable salt of said EP2 receptor selective agonist or of said prodrug.
A method of treating a condition which presents with low bone mass in a mammal comprising administering to said mammal an effective amount of an EP2/EP4 receptor selective agonist, a prodrug thereof or a pharmaceutically acceptable salt of thereof or of said prodrug.
A kit comprising:
Dependencies are inferred from the claim text.